Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Opt Express ; 18(16): 16335-44, 2010 Aug 02.
Artigo em Inglês | MEDLINE | ID: mdl-20721020

RESUMO

We present a study of the optical properties of three-armed square nanospirals made of silver and realized as nanostructured thin films with Glancing Angle Deposition. Calculation of current flows in the nanospirals show excited resonant modes resembling those observed in U-shaped resonators. Four principal resonances were determined: near 200 THz and 480 THz for one polarization and 250 THz and 650 THz for the polarization orthogonal to the first one. In particular, a mode with anti-parallel current flow in opposite arms, associated with the observed resonance near 650 THz, indicates the existence of a magnetic-like resonance in the square nanospiral arrays. The robustness of the resonances against variations in the structural parameters of the nanospirals was investigated. This study revealed that the main parameter driving the position of the resonances was the overall dimension of the nanospiral, directly related to the length of their arms. Optical properties of a sample were measured by generalized spectroscopic ellipsometry at near-normal incidence, and evidence conversion between polarization states even for light polarized in the plane containing one of the arms in agreement with the numerical study. The measurements compared favorably to the results of the numerical simulations taking into account the disorder in the sample.


Assuntos
Simulação por Computador , Luz , Nanoestruturas/química , Espalhamento de Radiação , Prata/química , Desenho de Equipamento , Magnetismo
2.
Endocrinology ; 130(5): 2725-32, 1992 May.
Artigo em Inglês | MEDLINE | ID: mdl-1315256

RESUMO

In the neonatal rat, the response of the hypothalamo-pituitary-adrenal axis to stressful stimuli is markedly decreased during the first 2 weeks of life. This peculiar period was named "stress hyporesponsive period." In this report, we studied the effect of insulin-induced hypoglycemia, known as a strong stimulator of the corticotroph function in the adult rat. Rats (8- or 20-day-old) were injected ip with 3 IU/kg synthetic insulin and were killed at various times. In 20-day-old rats, hypoglycemia induced a rapid drop in blood glucose concentrations accompanied by a stimulation of ACTH and corticosterone secretion which reached maximal values within 30 min. On the opposite, in 8-day-old rats, despite a rapid decrease in blood glucose levels, insulin injection induced a gradual rise of plasma ACTH and corticosterone concentrations which peaked at 90 min. This delayed response of the hypothalamo-pituitary-adrenal axis to hypoglycemia in the youngest rats does not seem to be due to a difference of sensitivity to insulin-induced hypoglycemia since injection of increasing doses of insulin (0.3, 0.75, or 3 IU/kg body wt) induced a dose-related decrease of blood glucose concentrations and a rise in plasma ACTH and corticosterone levels, comparable in the two age group studied. Basal or hypoglycemia-stimulated absolute corticosterone values were much lower in 8-day-old rats than in 20-day-old animals, suggesting an immaturity of the adrenal glands in the youngest animals. Daily ACTH injection, starting 3 days before the experiment, had a trophic effect on the adrenal glands leading to a more important increase of corticosterone levels after hypoglycemia in 8-day-old rats. Our results confirm that there is an immaturity of the adrenal glands in young rats, probably due to the low plasma ACTH levels during the neonatal period. To determine the respective role of the two major hypothalamic ACTH secretagogues, we studied the effect of passive immunization against CRF or arginine vasopressin (AVP) on plasma ACTH response after hypoglycemia. Passive immunization against AVP decreased significantly hypoglycemia-stimulated ACTH secretion in both 8- and 20-day-old rats, while no change of plasma ACTH response to insulin injection was observed after passive immunization against CRF. This results suggest that CRF does not seem to be involved in the regulation of ACTH secretion after hypoglycemia in the young rat while AVP seems to be the main hypothalamic stimulatory factor for anterior pituitary corticotrophs response to hypoglycemia during the postnatal period.(ABSTRACT TRUNCATED AT 400 WORDS)


Assuntos
Glândulas Suprarrenais/fisiologia , Hormônio Adrenocorticotrópico/metabolismo , Arginina Vasopressina/fisiologia , Glicemia/metabolismo , Corticosterona/metabolismo , Hormônio Liberador da Corticotropina/fisiologia , Hiperglicemia/fisiopatologia , Imunização Passiva , Insulina/farmacologia , Glândulas Suprarrenais/efeitos dos fármacos , Glândulas Suprarrenais/crescimento & desenvolvimento , Hormônio Adrenocorticotrópico/sangue , Hormônio Adrenocorticotrópico/farmacologia , Envelhecimento , Animais , Arginina Vasopressina/imunologia , Corticosterona/sangue , Hormônio Liberador da Corticotropina/imunologia , Hiperglicemia/induzido quimicamente , Cinética , Ratos , Ratos Endogâmicos , Proteínas Recombinantes/farmacologia , Valores de Referência , Fatores de Tempo
3.
Endocrinology ; 130(5): 3007-14, 1992 May.
Artigo em Inglês | MEDLINE | ID: mdl-1315264

RESUMO

ACTH and cortisol diurnal variations and responses to two types of stress (insulin-induced hypoglycemia and isolation-restraint stress) and to an acute injection of CRF were determined in intact as well as in actively antiarginine vasopressin (AVP)-immunized rams. All immunized sheep developed antibodies to AVP, displayed diabetes insipidus, and looked healthy in spite of their lower gain weight. Basal secretion and diurnal variations of ACTH and cortisol were unaltered in the group of anti-AVP-immunized animals. In contrast, ACTH and cortisol responses to both types of stress and CRF injection were significantly reduced compared to those in controls. These results suggest that endogenous AVP plays a physiological role in the corticotropic response to stress. However, endogenous AVP does not appear to affect basal secretion and diurnal variations of ACTH and cortisol.


Assuntos
Hormônio Adrenocorticotrópico/metabolismo , Arginina Vasopressina/fisiologia , Ritmo Circadiano , Hormônio Liberador da Corticotropina/farmacologia , Hidrocortisona/metabolismo , Imunização Passiva , Sistema Hipófise-Suprarrenal/fisiologia , Hormônio Adrenocorticotrópico/sangue , Análise de Variância , Animais , Arginina Vasopressina/imunologia , Glicemia/metabolismo , Peso Corporal , Diabetes Insípido/fisiopatologia , Comportamento de Ingestão de Líquido , Hidrocortisona/sangue , Hipoglicemia/induzido quimicamente , Hipoglicemia/fisiopatologia , Insulina/farmacologia , Masculino , Sistema Hipófise-Suprarrenal/efeitos dos fármacos , Sistema Hipófise-Suprarrenal/fisiopatologia , Restrição Física , Ovinos , Estresse Fisiológico/fisiopatologia , Estresse Psicológico/fisiopatologia
4.
Endocrinology ; 130(4): 2291-8, 1992 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-1312453

RESUMO

ACTH and cortisol diurnal variations and responses to two types of stress (insulin-induced hypoglycemia and isolation-restraint stress) or to an acute injection of lysine-vasopressin were studied in intact and anti-corticotropin-releasing factor (CRF) actively immunized rams. Immunization was obtained by the injection of synthetic ovine CRF coupled to BSA with carbodiimide. All animals developed antibodies anti-CRF and displayed an alteration of their general condition and a body weight reduction. The mean basal ACTH and cortisol secretion as well as the number and mean amplitude of diurnal pulses of these hormones was significantly reduced in the group of anti-CRF immunized rams. However, the reduction in all three parameters was much more pronounced for cortisol than for ACTH. No ACTH and cortisol response to insulin-induced hypoglycemia and isolation-restraint stress was observed. The stimulating action of lysine-vasopressin on ACTH release was significantly reduced as compared to controls. These results indicate that CRF is a major physiological component of the ovine hypothalamo-hypophysial-adrenal axis and participates in the events that regulate ACTH and cortisol diurnal variations and response to stress.


Assuntos
Hormônio Adrenocorticotrópico/metabolismo , Hormônio Liberador da Corticotropina/fisiologia , Hidrocortisona/metabolismo , Sistema Hipófise-Suprarrenal/fisiologia , Hormônio Adrenocorticotrópico/sangue , Animais , Ritmo Circadiano , Hormônio Liberador da Corticotropina/imunologia , Hidrocortisona/sangue , Hipoglicemia/metabolismo , Soros Imunes/imunologia , Imunização , Lipressina/farmacologia , Masculino , Ovinos
5.
Ann Endocrinol (Paris) ; 56(3): 213-8, 1995.
Artigo em Francês | MEDLINE | ID: mdl-7677407

RESUMO

A long-acting depot formulation of octreotide (Sandostatin LAR, Sandoz LTD) has been recently developed. Preliminary studies indicated that, in acromegalic patients previously controlled by Sandostatin 300-600 micrograms/day in 2-3 sc injections, the intramuscular administration of 20-30 mg of Sandostatin LAR achieved, during one month a similar control of GH hypersecretion. In the present study, the variations of plasma levels of octreotide, GH and IGF1 were followed during 2 months in acromegalic patients receiving a unique injection of 20 mg (n = 4) or 30 mg (n = 4) of Sandostatin LAR. Following Sandostatin LAR 20 mg i.m, the baseline values of GH (8.1 +/- 2.5 micrograms/l) and IGF1 (684 +/- 92 micrograms/l) were normalized after 2 weeks and remained into the normal range during the 28 following days. Similar results were obtained, after a 30 mg i.m administration of Sandostatin LAR. In this later case, the maximal inhibition of GH and IGF1 (1.3 +/- 1.0 micrograms/l and 392 +/- 266 micrograms/l respectively) lasted 2 months. These data showed that a monthly injection of Sandostatin LAR (20-30 mg) allowed a correct control of GH hypersecretion in this series of acromegalic patients.


Assuntos
Acromegalia/tratamento farmacológico , Octreotida/uso terapêutico , Antineoplásicos/farmacocinética , Método Duplo-Cego , Tolerância a Medicamentos , Feminino , Hormônio do Crescimento/sangue , Humanos , Fator de Crescimento Insulin-Like I/farmacocinética , Masculino , Pessoa de Meia-Idade , Octreotida/farmacocinética , Octreotida/farmacologia
7.
Acta Endocrinol (Copenh) ; 128(5): 466-72, 1993 May.
Artigo em Inglês | MEDLINE | ID: mdl-8317194

RESUMO

The regulation of anterior pituitary adrenocorticotropin hormone (ACTH) secretion during stress involves several hypothalamic neurohormones, including arginine vasopressin (AVP). In situ hybridization techniques have been used to study the regulation of neuropeptide messenger ribonucleic acids in the hypothalamus. Owing to the relatively slow time course of the changes in cytoplasmic messenger ribonucleic acid concentrations, rapid alterations in the level of neuropeptide gene transcription could not be detected. Because of its rapid processing, the nuclear level of the heteronuclear ribonucleic acid should reflect the rate of its synthesis, namely the transcription of the gene. We have used in situ hybridization with a probe complementary to a portion of an intronic sequence of the rat AVP gene to study rapid changes in the level of AVP gene transcription during emotional stress. The specificity of our technique was demonstrated by the localization of the hybridization signals in the paraventricular nucleus, the supraoptic nucleus and the suprachiasmatic nucleus, and was confirmed by the nuclear localization of the labeling. Isolation and exposure of male rats to a novel environment induced an activation of the pituitary-adrenal axis and an increase in AVP heteronuclear ribonucleic acid concentrations in the paraventricular nucleus 2 h after the onset of the stress, suggesting that an increased AVP gene transcription may play a role in the activation of the pituitary-adrenal axis in response to emotional stress.


Assuntos
Arginina Vasopressina/genética , Núcleo Hipotalâmico Paraventricular/metabolismo , RNA Nuclear Heterogêneo/biossíntese , Estresse Psicológico/metabolismo , Transcrição Gênica , Animais , Arginina Vasopressina/biossíntese , Corticosterona/biossíntese , Regulação da Expressão Gênica , Hibridização In Situ , Masculino , Sondas de Oligonucleotídeos , RNA Mensageiro/biossíntese , Ratos , Ratos Sprague-Dawley
8.
Clin Endocrinol (Oxf) ; 43(2): 213-7, 1995 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-7554317

RESUMO

OBJECTIVE: Previous studies have shown that non-glycosylated prolactin (NG-PRL) increased more markedly than glycosylated hormone (G-PRL) after TRH or metoclopramide stimulation. The aim of the present study was to determine whether such results could be extended to opioid-induced PRL stimulation. DESIGN: Open and prospective study. Using a newly developed IRMA specific for NG-PRL, we determined G-PRL and NG-PRL immunoreactivities after administration of 0.8-1.2 mg of the opioid drug phenoperidine as part of an anaesthesia. PATIENTS: Ten male patients anaesthetized for surgical treatment of a prolapsed lumbar intervertebral disc. MEASUREMENTS: Samples were obtained hourly pre and post-operatively, and every 15 minutes during operation for determination of plasma PRL, NG-PRL and G-PRL. Plasma cortisol, ACTH and GH levels were measured in an attempt to differentiate the respective roles of stress and opiate agonists in the variations of PRL levels during surgery. RESULTS: A dramatic increase in PRL levels was observed in all patients from an average of 300 +/- 90 to 1200 +/- 330 mU/l (mean + SEM) 30 minutes after drug administration. The proportion of G-PRL immunoreactivity was not significantly different when basal (25.2%) and stimulated (27%) values were compared (P > 0.05), and when mean increments of NG-PRL and G-PRL were compared (345 and 348%, respectively). The opioid drug induced a significant decrease in cortisol levels after injection and during operation (from 585 +/- 63 to 99 +/- 51 nmol/l) with a concomitant decrease in ACTH levels. GH levels were not significantly altered during anaesthesia but were significantly greater (P < 0.05) after than before surgery (5.0 +/- 1.3 vs 0.98 +/- 0.54 mU/l, respectively). CONCLUSIONS: We conclude from the present and from previous data that opioid induced anaesthesia is accompanied by an increase in both glycosylated and non-glycosylated PRL and that different PRL secretagogues may induce distinct responses in terms of PRL molecular forms.


Assuntos
Anestesia Geral , Fenoperidina/farmacologia , Prolactina/análogos & derivados , Prolactina/sangue , Adulto , Glicosilação , Humanos , Hidrocortisona/sangue , Ensaio Imunorradiométrico , Masculino , Estudos Prospectivos , Estimulação Química , Estresse Fisiológico/sangue , Procedimentos Cirúrgicos Operatórios
9.
Horm Res ; 38(1-2): 84-9, 1992.
Artigo em Inglês | MEDLINE | ID: mdl-1306523

RESUMO

Among 288 patients with prolactinoma (aged 12-62 years; 242 women), 27 were diagnosed as resistant to bromocriptine as their plasma prolactin (PRL) levels remained elevated despite long-term (3 months or more) treatment at high doses (> or = 15 mg daily). These 18 women and 9 men, aged 29 +/- 9 years (mean +/- SD, range 13-50), followed-up for 8 +/- 4 years, had microadenomas (n = 6) or macroadenomas. They were treated by dopamine agonists alone (n = 6) or associated with surgical or radiation therapy. In 8 cases repetitive surgical treatments were necessary. Among the 24 patients who were treated with the nonergot dopamine agonist CV 205-502 after unsuccessful bromocriptine treatment, half of them (9 women, 3 men) resumed normal PRL levels on doses ranging from 0.15 to 0.45 mg/day. Despite daily doses of CV 205-502 from 0.3 to 0.525 mg, the remaining patients were not normalized by this drug which did not prevent tumor growth in 4 of them. Two patients died from invasive cerebral extensions of their tumor and a third had vertebral metastases with positive anti-PRL immunostaining. It is concluded that bromocriptine-resistant prolactinomas represent the most severe aspect of this disease and that a more powerful dopamine agonist like CV 205-502 is effective in only a fraction of these patients.


Assuntos
Bromocriptina/uso terapêutico , Resistência a Medicamentos , Neoplasias Hipofisárias/tratamento farmacológico , Prolactinoma/tratamento farmacológico , Adolescente , Adulto , Aminoquinolinas/uso terapêutico , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Hipofisárias/radioterapia , Neoplasias Hipofisárias/cirurgia , Prolactina/sangue , Prolactinoma/radioterapia , Prolactinoma/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA